[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial

Hemerion joins Neighborhood

Hemerion joins the Voisin Consulting Neighborhood program, a life science innovation center that offers tailored mentoring, coaching and global access to health tech entrepreneurs.

I-Lab innovation competition

Hemerion is awarded during I-Lab innovation competition and granted to upgrade its lead product and better meet neurosurgeons needs.  

Patients enrollment successfully completed

The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with  Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.

European Neurosurgery Congress

The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.

Awarded by world’s largest medical laser society

M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.


Kick-off of phase I clinical trial: INDYGO

For the first time, our technology combining a photosensitizing drug and an innovative photonic device is delivered upfront, during the surgery of patients newly diagnosed with glioblastoma.  Indygo is a Phase I study sponsored by the University Hospital of Lille.